Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (60)	5/29/2001 12:40:18 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1005

>> BLUE HP is looking for hell to take RIGL to 5 or so. << This will be an interesting test....... massive supply, but better sentiment. I haven't a clue of what will happen. Yes, I use Excel. However, it's such an old version that I can't open any of the stuff that I receive by email these days. So..... effective answer to your question is probably "no". INCR, MEDI, <your pet peeve slowpoke biotech here> grrrrrrrrrr................

To: tuck who wrote (60)	5/29/2001 10:08:34 AM
From: tuck	Respond to of 1005

Quite the drama we've had on RIGL already. Hit my expectation on the first day. BLUE HP is a definite buyer under 4 . . . Meanwhile BLUE HP candidate CIPH launches products: >>FREMONT, Calif., May 29 /PRNewswire/ -- Ciphergen Biosystems Inc. (Nasdaq: CIPH - news) announced today at the 49th Annual Conference on Mass Spectrometry and Allied Topics in Chicago an expanded product portfolio to address the needs of both clinical and basic research proteomics laboratories. Ciphergen introduced: A new SELDI (surface enhanced laser desorption/ionization) ProteinChip interface to high-end quadrupole time-of-flight tandem mass spectrometers that enables ``on-chip,'' high performance protein identification, epitope and phosphorylation mapping and protein interaction analyses. New Biomarker Patterns(TM) Software which enables pattern recognition analysis of protein expression profiles generated by Ciphergen's ProteinChip System and Arrays. New high performance ProteinChip Arrays that feature state-of-the-art hydrophilic polymer surfaces that provide greatly improved selectivity, sensitivity and reproducibility for ProteinChip Proteomics applications. New ProteinChip Arrays which have been packaged into a series of application-specific kits to enhance ease-of-use for the biologist performing protein analysis. ``These new products provide significant improvements in protein expression profiling, protein interaction and protein identification applications,'' said Richard B. Rubin, Director of Marketing for Ciphergen. ``Combined with our ProteinChip System, the new SELDI interface for tandem MS will complement both affinity LC-MS and 2-D gel methods used in basic research and drug discovery proteomics.'' Commenting on the new tandem MS interface program, Dr. William E. Rich, President and CEO of Ciphergen said, ``We've successfully demonstrated the utility of the ProteinChip-Tandem MS interface in several projects in our Fremont Biomarker Center and with key customers over the past year. ProteinChip-Tandem MS capability works in harmony with our existing technology allowing researchers to take a sample that's been profiled 'on-chip' directly to the tandem MS for peptide fragmentation-based sequence analysis.'' Furthermore, Dr. Rich noted, ``We believe Clinical Proteomics, pioneered by Ciphergen, will particularly benefit from the new pattern recognition software. The Biomarker Patterns Software module that is being launched addresses a key component of the biomarker discovery process. A major benefit of the ProteinChip platform is in the discovery and correlation of multiple biomarkers in a population of samples to rapidly validate clinical, toxicological and cell pathway pathology. As was the case in the development of DNA array technology, the flood of data produced by the instrument makes informatics tools critical to interpreting the results. The new software package combined with an updated 'Biomarker Wizard' in Ciphergen's core software package automatically identifies multiple protein peaks that correlate with phenotype differences between samples. The new line of ProteinChip Arrays improves both the total number of proteins detected from a single sample as well as the data reproducibility from run-to-run. In combination with pattern recognition analysis, these array improvements create high clinical statistical confidence in sample stratification results.'' Ciphergen also announced a new line of ProteinChip Kits making it easier for new users of the system to adopt the technology and achieve reliable results. The first kits to be released address key applications including protein profiling, peptide mapping, antibody capture and a beta-amyloid multipeptide assay for Alzheimer's research. These kits consist of specific arrays, reagents and an optimized protocol.<< snip Cheers, Tuck